Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ganglioside-Monosialic Acid Prophylaxis for Cognitive Dysfunction Related to Whole Brain Radiotherapy in Breast Cancer Patients With Brain Metastases ，a Multi-center，Randomized，Single Blind，Phase III Clinical Trail

NCT04395339 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT04395339
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04395339 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ganglioside-Monosialic Acid Prophylaxis for Cognitive Dysfunction Related to Whole Brain Radiotherapy in Breast Cancer Patients With Brain Metastases ，a Multi-center，Randomized，Single Blind，Phase III Clinical Trail
Lead sponsor
Sun Yat-sen University
Phase
Phase 3
Overall status
Terminated
Start date
May 15, 2020
Completion date
July 31, 2024
Enrollment
51 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases, breast cancer, cognitive impairment, gangliosidosis, gm1, radiotherapy side effect